Addition of Ribociclib to Nonsteroidal Aromatase Inhibitor Benefits Broad Range of Patients With HR-Positive, HER2-Negative Early Breast Cancer
Recommended
Addition of Ribociclib to Nonsteroidal Aromatase Inhibitor Benefits Broad Range of Patients With HR-Positive, HER2-Negative Early Breast Cancer
In this video, Dr Aditya Bardia discusses results from a subgroup analysis of the phase 3 NATALEE study comparing invasive disease-free survival across a broad range of patients with HR-positive, HER2-negative early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor.
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->